कंपनी का अवलोकन
MacroGenics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on the discovery, development, manufacturing, and commercialization of antibody-based therapeutics designed for cancer treatment within the United States. The company functions within the healthcare sector, specifically under the biotechnology industry, where its primary objective is advancing the pipeline of bispecific DART molecules such as lorigerlimab to target immune checkpoint pathways. Currently, the organization employs a workforce of 293 individuals to execute its research and commercialization strategies while maintaining a total market capitalization of $218.65M. With a trailing twelve-month revenue of $149.50M, these valuation and revenue metrics position MacroGenics as a mid-cap entity that has recently achieved significant top-line expansion, although its market cap remains constrained by ongoing clinical development expenditures and the inherent risks associated with late-stage biotechnology asset classes.
वित्तीय स्वास्थ्य
The company reported a revenue of $149.50M over the trailing twelve-month period, yet recorded a net income of -$74,620,000 and an EBITDA of -$65,669,000, revealing a substantial disparity between top-line sales and bottom-line profitability. This wide gap between revenue and net income indicates a heavy cost structure driven by high research and development expenses, sales and marketing outlays, and general administrative costs typical of a clinical-stage biopharmaceutical firm. Free cash flow stands at -$58,232,124, which signifies that the company is currently burning cash to fund its operations and pipeline progression rather than generating surplus liquidity for shareholder distributions. The gross margin is reported at -22.5%, while the operating margin sits at -29.3% and the profit margin reaches -49.9%, collectively demonstrating that the company is operating at a loss on nearly every dollar of revenue generated before considering interest and taxes. On the balance sheet, MacroGenics holds $189.91M in cash against $36.76M in debt, resulting in a debt-to-equity ratio of 66.13 that suggests a leveraged position relative to equity but provides a robust liquidity buffer for near-term obligations. The current ratio is 5.10, indicating that the company possesses more than five times the current assets necessary to cover its short-term liabilities, which points to strong short-term liquidity despite operational losses. Furthermore, the return on equity is -86.9% and the return on assets is -17.6%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and creditors, a common characteristic for early-phase biotechnology companies prioritizing growth over immediate profitability.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, whereas the forward P/E is -3.55, a figure that implies the market is pricing in an expectation of future earnings recovery or is utilizing a different metric framework for valuation given the current losses. The price-to-book ratio stands at 3.92, indicating that the market values the company's equity at nearly four times its net book value, which often reflects the high value assigned to intangible assets like intellectual property and the clinical pipeline rather than tangible assets. Alternative valuation metrics include a price-to-sales ratio of 1.46 and an EV/EBITDA of -1.00, suggesting that investors are valuing the firm based on its revenue generation potential and cash burn rate rather than current profitability, which is standard for clinical-stage assets. The stock has traded within a 52-week range bounded by a high of $3.54 and a low of $1.02, meaning the current valuation sits somewhere within this historical volatility band, reflecting the high-risk profile associated with biotechnology equities. The beta value is 1.10, which indicates that the stock's price volatility is 10% higher than the broader market, exposing investors to greater fluctuations in share price relative to systemic market movements.
Growth & Income
MacroGenics, Inc. has demonstrated robust revenue growth of 113.0% year-over-year, while earnings growth is listed as N/A due to the absence of positive net income to compound. Since the earnings growth metric is unavailable, the disparity between the explosive revenue expansion and the inability to show earnings growth implies that the company is still in the capital-intensive phase of commercializing its therapeutic candidates. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow is being reinvested into the research and development of its antibody-based therapeutics and the advancement of its product pipeline. Consequently, the overall growth and income profile of MacroGenics is characterized by aggressive top-line scaling funded by internal cash reserves and external capital markets, with no current income distribution to shareholders.